{
    "nct_id": "NCT05080218",
    "official_title": "The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy",
    "inclusion_criteria": "*Patients must meet all of the inclusion criteria at the time of screening*\n\n* Must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions:\n\n  * Rheumatoid arthritis or adults previously diagnosed with Juvenile idiopathic arthritis (analyzed as a single category)\n  * Psoriatic arthritis (PsA), Ankylosing spondylitis (ASp), or other Spondyloarthritis (SpA)\n* Must have completed the 2-dose regimen of either of the two mRNA COVID-19 vaccines more than 28 days previous to enrollment\n* Must be scheduled for an additional dose of mRNA COVID-19 vaccination booster (or with plans to schedule booster) within the next 30 days\n* Must have a cell phone capable of receiving text messages, and/or a personal email address\n* Currently receiving one of the medications described in Table 1\n* Must be on stable immunomodulatory therapy for 8 weeks (with no dose changes, or interruptions > 2 weeks) prior to study enrollment. This would include both the qualifying immunomodulatory drug listed in Table 2, as well as any background immunomodulatory therapies (e.g. methotrexate, leflunomide) or glucocorticoids.\n* Must be 18 years of age or older\n* Must live in the United States.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* â€¢ Already received a non-mRNA COVID-19 vaccine dose (J&J)\n\n  * Any use in the past 90 days of a monoclonal antibody against COVID-19 (e.g., bamlanivimab, casirivimab, imdevimab)\n  * Any known contraindication to COVID-19 vaccination, including allergic reaction to prior COVID-19 vaccination, and severe allergy to vaccine components (e.g., pegloticase)\n  * Known HIV/AIDS or any other immunodeficient condition\n  * Use of immunomodulatory therapy for any non-rheumatologic indication (e.g., organ transplantation)\n  * Currently receiving radiation or chemotherapy for any type of malignancy.\n  * Receipt of any immunization other than COVID-19 within two weeks prior to the COVID-19 vaccine supplemental dose\n  * Significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to < 1 year)\n  * Any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g., uncontrolled disease flare, uncontrolled comorbidity)",
    "miscellaneous_criteria": ""
}